T-cell depletion of bone marrow grafts with Campath 1 ex vivo prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation

T-cell depletion of bone marrow grafts with Campath 1 ex vivo prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation

Bibliographic Details
Main Authors:	Novitzky, N, Thomas, V, Hale, G, Waldmann, H
Format:	Journal article
Published:	1997

Similar Items

Ex vivo T-cell depletion of bone marrow grafts with campath 1 prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation.
by: Novitzky, N, et al.
Published: (1997)

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect.
by: Novitzky, N, et al.
Published: (1999)

In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
by: Willemze, R, et al.
Published: (1992)

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
by: Heit, W, et al.
Published: (1986)

T-CELL DEPLETION BY EXPOSURE TO CAMPATH-1G IN-VITRO PREVENTS GRAFT-VERSUS-HOST DISEASE
by: Jacobs, P, et al.
Published: (1994)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
by: Hale, G, et al.
Published: (1988)

T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.
by: Jacobs, P, et al.
Published: (1994)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
by: Hale, G, et al.
Published: (1994)

T-cell depletion of stem cell grafts with campath-1H "in the bag" followed by cyclosporin immunosuppression remains a cost effective strategy in transplantation
by: Novitzky, N, et al.
Published: (2004)

CAMPATH-1 FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT-REJECTION - SUMMARY OF RESULTS FROM A MULTI-CENTRE STUDY
by: Hale, G, et al.
Published: (1988)

Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo.
by: Cobbold, S, et al.
Published: (1986)

Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
by: Apperley, J, et al.
Published: (1986)

Availability of Campath-1 antibodies for bone marrow transplantation.
by: Hale, G, et al.
Published: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
by: Hale, G, et al.
Published: (1994)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
by: Hale, G, et al.
Published: (1998)

Addition of cyclosporin post transplantation decreases GvHD without enhancing the adverse effect of T-cell depletion with CAMPATH-1H "in the bag": The cape town experience
by: Novitzky, N, et al.
Published: (2003)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
by: Hale, G, et al.
Published: (1996)

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
by: Kottaridis, P, et al.
Published: (2000)

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).
by: Waldmann, H, et al.
Published: (1984)

RESULTS OF T-CELL DEPLETION WITH CAMPATH-1 IN BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL)
by: Apperley, J, et al.
Published: (1985)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
by: Fibbe, W, et al.
Published: (1993)

Myeloablative conditioning is well tolerated by older patients receiving T-cell depleted grafts
by: Novitzky, N, et al.
Published: (2005)

Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts.
by: Novitzky, N, et al.
Published: (2005)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
by: Waldmann, H, et al.
Published: (1987)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
by: Waldmann, H, et al.
Published: (1985)

Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
by: Slavin, S, et al.
Published: (1987)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
by: Waldmann, H, et al.
Published: (1985)

PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION
by: Slavin, S, et al.
Published: (1985)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
by: Chakrabarti, S, et al.
Published: (2003)

CAMPATH-1 antibodies in stem-cell transplantation.
by: Hale, G, et al.
Published: (2001)

Extract Mitigates Experimental Acute Graft versus Host Disease Without Abrogating Graft Versus Leukemia Effect
by: Saurabh Kumar Gupta, et al.
Published: (2024-01-01)

Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects
by: Grégory Ehx, et al.
Published: (2017-05-01)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
by: Buggins, A, et al.
Published: (2001)

Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia.
by: Novitzky, N, et al.
Published: (2004)

Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia.
by: Novitzky, N, et al.
Published: (2004)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
by: Novitzky, N, et al.
Published: (2004)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
by: Newman, D, et al.
Published: (1995)

Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
by: Hamblin, M, et al.
Published: (1996)

CAMPATH: from concept to clinic.
by: Waldmann, H, et al.
Published: (2005)

In marrow aplasia reduced-intensity conditioning and T-cell depletion of cytokine mobilised stem cells provides good engraftment without GvHD
by: Novitzky, N, et al.
Published: (2006)